Assignee
AROG PHARMACEUTICALS INC
US·24 granted patents·14 pending applications·78 citations·filing 2015–2025
Top patents by PatentIndex Score
38 records- 0195US12171757B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2022·Granted Dec 24, 2024·1 cites·19 claims
- 0295US10780086B2Method of inhibiting constitutively active phosphorylated FLT3 kinaseAROG PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·6 cites·29 claims
- 0395US10213423B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2017·Granted Feb 26, 2019·14 cites·29 claims
- 0494US9801870B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2016·Granted Oct 31, 2017·12 cites·43 claims
- 0594US9801869B2Method of inhibiting constitutively active phosphorylated FLT3 kinaseAROG PHARMACEUTICALS INC·Filed 2015·Granted Oct 31, 2017·14 cites·37 claims
- 0692US10835525B2Method of inhibiting mutant C-KITAROG PHARMACEUTICALS INC·Filed 2019·Granted Nov 17, 2020·5 cites·23 claims
- 0792US2025032475A1Crenolanib for Treating FLT3 Mutated Proliferative DisordersAROG PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0891US11078541B2Crenolanib for treating FLT3 mutated proliferative disorders associated mutationsAROG PHARMACEUTICALS INC·Filed 2017·Granted Aug 3, 2021·3 cites·21 claims
- 0991US9889127B2Method of inhibiting mutant C-KITAROG PHARMACEUTICALS INC·Filed 2016·Granted Feb 13, 2018·9 cites·24 claims
- 1090US10251877B2Method of inhibiting mutant C-KITAROG PHARMACEUTICALS INC·Filed 2018·Granted Apr 9, 2019·7 cites·24 claims
- 1188US11969420B2Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disordersAROG PHARMACEUTICALS INC·Filed 2021·Granted Apr 30, 2024·1 cites·13 claims
- 1288US11524006B2Crenolanib for treating TRK kinase associated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2021·Granted Dec 13, 2022·1 cites·21 claims
- 1388US11007188B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2019·Granted May 18, 2021·1 cites·28 claims
- 1487US11738017B2Method of inhibiting constitutively active phosphorylated FLT3 kinaseAROG PHARMACEUTICALS INC·Filed 2020·Granted Aug 29, 2023·1 cites·21 claims
- 1587US11458131B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2020·Granted Oct 4, 2022·1 cites·22 claims
- 1686US11642340B2Method of inhibiting mutant C-KITAROG PHARMACEUTICALS INC·Filed 2020·Granted May 9, 2023·1 cites·25 claims
- 1784US2025305063A1Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated MutationsAROG PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1883US2023338360A1Method of Inhibiting Constitutively Active Phosphorylated FLT3 KinaseAROG PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1982US12383549B2Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disordersAROG PHARMACEUTICALS INC·Filed 2024·Granted Aug 12, 2025·0 cites·8 claims
- 2077US11602533B2Crenolanib combination therapyAROG PHARMACEUTICALS INC·Filed 2019·Granted Mar 14, 2023·1 cites·34 claims
- 2176US12404555B2Crenolanib for treating FLT3 mutated proliferative disorders associated mutationsAROG PHARMACEUTICALS INC·Filed 2021·Granted Sep 2, 2025·0 cites·5 claims
- 2274US12295948B2Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatmentAROG PHARMACEUTICALS INC·Filed 2023·Granted May 13, 2025·0 cites·5 claims
- 2373US2025345322A1Novel combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disordersAROG PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2472US12486256B2Crystal forms of crenolanib and methods of use thereofAROG PHARMACEUTICALS INC·Filed 2023·Granted Dec 2, 2025·0 cites·7 claims
- 2572US2023241052A1Method of inhibiting mutant c-kitAROG PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2672US2023181565A1Crenolanib combination therapyAROG PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2771US2023060673A1Crenolanib for treating trk kinase associated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2870US11857546B2Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatmentAROG PHARMACEUTICALS INC·Filed 2022·Granted Jan 2, 2024·0 cites·9 claims
- 2970US2023000856A1Novel uses of crenolanibAROG PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3069US11713310B2Crystal forms of crenolanib and methods of use thereofAROG PHARMACEUTICALS INC·Filed 2021·Granted Aug 1, 2023·0 cites·16 claims
- 3161US11471451B2Uses of crenolanibAROG PHARMACEUTICALS INC·Filed 2020·Granted Oct 18, 2022·0 cites·31 claims
- 3260US2025161293A1Crenolanib for treating flt3 mutated proliferative disorders relapsed/refractory to prior treatmentAROG PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3359US12534764B2Crenolanib for treating FLT3 mutated proliferative disorders associated mutationsAROG PHARMACEUTICALS INC·Filed 2021·Granted Jan 27, 2026·0 cites·13 claims
- 3458US2022218694A1Crenolanib for treating flt3 mutated proliferative disorders associated mutationsAROG PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3556US2022047574A1Crenolanib for treating pdgfr alpha mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3656US2022047577A1Crenolanib for treating pdgfr alpha mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3756US2022079934A1Crenolanib for treating painAROG PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3854US2021145823A1Crenolanib for treating flt3 mutated proliferative disorders associated mutationsAROG PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →